Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24849230 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL10470330 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL1751993 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL19163738 | 0.82 | SMN1; SMN2 (0.68) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL7221502 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL24849367 | 0.80 | MIF (0.41) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL24849172 | 0.78 | GABRA1 (0.43) | SMN1; SMN2L3MBTL1ATMALDH1A1KDM4E | |
| SCHEMBL5835024 | 0.78 | TDP1 (0.55) | SMN1; SMN2L3MBTL1ATMKDM4E | |
| SCHEMBL2058958 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| Hydrochloric Acid SCHEMBL7314768 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| CN-119874561-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-113950471-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230107360-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2023-04-06 | — | — | US | disclosed |
| US-11603355-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-03-14 | — | — | US | disclosed |
| WO-2023274258-A1 | HETEROATOM-SUBSTITUTED AROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川大学华西医院 | 2023-01-05 | — | — | WO | disclosed |
| US-11512058-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-11-29 | — | — | US | disclosed |
| CN-113811305-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2021-12-17 | — | — | CN | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10934263-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2020185830-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020185881-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200290979-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-7101912-B2 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XENOPORT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XIANG JIA-NING (US) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | SMN1; SMN2 2763/4885L3MBTL1 4844/4885KMT2A 2429/4885 |
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | PDE3A, ADORA2A, CDA | SMN1; SMN2 3457/4885L3MBTL1 2983/4885KMT2A 1867/4885 |
| US-11512058-B2 | Charged ion channel blockers and methods for use | TRPV1, ASIC1, TRPA1 | SMN1; SMN2 2906/4885L3MBTL1 4837/4885KMT2A 3122/4885 |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | SMN1; SMN2 2763/4885L3MBTL1 4844/4885KMT2A 2429/4885 |
| US-10934263-B2 | Charged ion channel blockers and methods for use | TRPV1, ASIC1, TRPA1 | SMN1; SMN2 2906/4885L3MBTL1 4837/4885KMT2A 3122/4885 |
| US-20200290979-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, ASIC1, TRPA1 | SMN1; SMN2 2906/4885L3MBTL1 4837/4885KMT2A 3122/4885 |
| US-11603355-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | SMN1; SMN2 2763/4885L3MBTL1 4844/4885KMT2A 2429/4885 |
| US-20230107360-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | SMN1; SMN2 3039/4885L3MBTL1 4852/4885KMT2A 3311/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | SMN1; SMN2 2763/4885L3MBTL1 4844/4885KMT2A 2429/4885 |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | OPRL1, TRPV1, SCN2B | SMN1; SMN2 1723/4885L3MBTL1 3942/4885KMT2A 3573/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | SMN1; SMN2 2763/4885L3MBTL1 4844/4885KMT2A 2429/4885 |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | SMN1; SMN2 2763/4885L3MBTL1 4844/4885KMT2A 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.